Grafa News and Videos — Page 77

Upbound Group (NASDAQ:UPBD) announced that its Board of Directors has approved a quarterly cash dividend of $0.39 per common share for the fourth quarter of 2026.

Mesoblast (NASDAQ:MESO) announced that the U.S. Food and Drug Administration (FDA) has approved the use of a new potency testing method for commercial batches of Ryoncil.

Satellos Bioscience (NASDAQ:MSLE) announced that it has received U.S. Food and Drug Administration (FDA) clearance to begin studying forazapadin in patients with facioscapulohumeral muscular dystrophy (FSHD).

Ligand Pharmaceuticals (NASDAQ:LGND) announced a financing agreement with AvenCell Therapeutics that could provide up to $47 million to support development of AvenCell’s cancer treatment pipeline.

IMUNON (NASDAQ:IMNN) presented Phase 2 survival results and Phase 3 enrollment updates for IMNN-001, its investigational therapy for advanced ovarian cancer.

Ainos (NASDAQ:AIMD) announced that it has entered into a VELDONA license agreement with BioPhoenix, establishing a conditional collaboration framework with a potential value of up to $10 million.

SLB (NYSE:SLB) announced that it has been awarded four integrated well construction contracts by Saudi Aramco to support oil and gas development projects across the Kingdom of Saudi Arabia.

Mobix Labs (NASDAQ:MOBX) announced that it expects fiscal fourth-quarter 2026 revenue to exceed the midpoint of its previous guidance range as demand improves across its wireless systems and connectivity businesses.

Pasqal (NYSE:PSQL) reported first-half 2026 revenue of €4.9 million for the six months ended June 30, 2026, representing a 14% increase compared with the prior-year period.

Acadia Pharmaceuticals (NASDAQ:ACAD) announced Phase 3-enabling topline results from the Phase 2 portion of its ongoing RADIANT clinical trial program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).